Results 171 to 180 of about 16,140,135 (309)
Case Report: Bilateral renal lymphangiomatosis with atypical manifestations in an elderly patient. [PDF]
Hu D, Yuan Y, Wang B, Li Y.
europepmc +1 more source
We show that the majority of the 18 analyzed recurrent cancer‐associated ERBB4 mutations are transforming. The most potent mutations are activating, co‐operate with other ERBB receptors, and are sensitive to pan‐ERBB inhibitors. Activating ERBB4 mutations also promote therapy resistance in EGFR‐mutant lung cancer.
Veera K. Ojala +15 more
wiley +1 more source
Afebrile Recurrent Cellulitis Complicated by Linezolid-Induced Lactic Acidosis in an Elderly Patient. [PDF]
Yambó-Chévere Y, Bermúdez-Rivera R.
europepmc +1 more source
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris +10 more
wiley +1 more source
Isolated Hepatic Hemangiomatosis Leading to Fatal Consumptive Coagulopathy in an Elderly Patient: A Case Report. [PDF]
Żyrek D, Oszytko JK, Chlebowska GM.
europepmc +1 more source
Non-verbal behaviour in nurse-elderly patient communication.
W. Caris-Verhallen +2 more
semanticscholar +1 more source
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang +3 more
wiley +1 more source
An Unusual Presentation of Nectrotizing Otitis Externa in an Elderly Patient. [PDF]
Apostol-DeJong I, Masood S, Binzar LC.
europepmc +1 more source
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat +8 more
wiley +1 more source

